Hepatobiliary surgery in the era of immunotherapy: integrating surgical timing, immune surveillance, and recurrence prevention - Takeaways - MDSpire

Hepatobiliary surgery in the era of immunotherapy: integrating surgical timing, immune surveillance, and recurrence prevention

  • By

  • Jingyi Xu

  • Lei Yang

  • Shuang Wang

  • Liusheng Wu

  • Yuehua Liang

  • Xialin Xie

  • Wenqiang Wang

  • Lu Gao

  • Jun Yan

  • July 1, 2026

  • 0 min

Share

  • 1

    Hepatobiliary surgery decisions depend on tumor extent, liver reserve, and the influence of immunotherapy on surgical timing and approach.

  • 2

    Nivolumab and other immunotherapies have shown potential for pathological regression in hepatocellular carcinoma before resection.

  • 3

    Surgical timing is crucial, as operating too early or too late can impact outcomes, necessitating careful consideration of immune-related adverse events.

  • 4

    Immuno-surgical resectability integrates imaging and tumor markers to assess operability, differing by tumor type and immune response.

  • 5

    Transplant candidates require careful management of ICI washout periods to minimize rejection risk, with longer washouts generally preferred.

Original Source(s)

Hepatobiliary surgery in the era of immunotherapy: integrating surgical timing, immune surveillance, and recurrence prevention

  • by Jingyi Xu, Lei Yang, Shuang Wang, Liusheng Wu, Yuehua Liang, Xialin Xie, Wenqiang Wang, Lu Gao, Jun Yan

  • July 1, 2026

Related Content

CTSG-expressing mast cells confer resistance to immunotherapy in colorectal cancer

Optimizing immunotherapy in advanced gastric cancer: established and emerging biomarkers for precision patient selection

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis